HomeQuestion

Would you avoid use of JAK inhibitors in patients with dermatomyositis with autoantibody subtypes with increased risk of malignancy (TIF1y, NXP2)?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In patients with anti-PL7 antibody–associated antisynthetase syndrome, can sacroiliitis occur as part of the inflammatory arthritis spectrum, or should alternative causes be considered?

How would you approach rituximab dosing in a patient with SLE-Myositis overlap with LN Class III, now with worsening UPCR and concern for worsening ILD 4 months post induction and incomplete B-Cell depletion on recent labs?

How do you approach management and monitoring of a patient with features suggestive of early or incomplete antisynthetase syndrome (mechanics hands and positive antisynthetase antibody) but no objective evidence of myositis, arthritis, or ILD at presentation?

Is bortezomib associated with drug-induced myopathy?

How do you manage worsening cutaneous dermatomyositis when muscle disease appears controlled?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.